The Company has developed XenoMouse technology, a proprietary technology which produces antibodies with fully human protein sequences, generates a diverse antibody response to essentially any disease target appropriate for antibody therapy and high affinity antibodies that do not require further engineering. Abgenix also has four antibody product candidates that are under development internally. Abgenix, Inc. develops and intends to commercialize antibody therapeutic products for the treatment of a variety of disease conditions.
Revenues reflect higher interest income and contract revenues.
Higher losses suffered from an increase in research and development and interest expenses, and amortization of intangible assets charges. All Rights Reserved. Privacy Policy - Terms of Service Company information Copyright Market Guide . Some event data provided by StreetEvents . Data and information is provided for informational purposes only, and is not intended for trading purposes.